FrancophonIA/ELRC3.0 huggingface dataset:
English: Please read the following instructions carefully to learn how to use and care for your Onbrez Breezhaler inhaler.
Estonian: Palun lugege järgnevaid juhiseid tähelepanelikult, et teada saada, kuidas Onbrez Breezhaler inhalaatorit kasutada ja hooldada.
English: If you have questions about how long to continue your treatment with Onbrez Breezhaler, talk to your doctor or pharmacist.
Estonian: Kui teil on küsimusi selle kohta, kui kaua tuleb ravi Onbrez Breezhaler'iga jätkata, rääkige oma arsti või apteekriga.
English: Do not press the side buttons more than once.
Estonian: Ärge vajutage inhalaatori külgedel olevaid nuppe rohkem kui üks kord.
English: Mass balance was complete with ≥90% of the dose recovered in the excreta.
Estonian: Massitasakaal oli täielik, kuna ≥90% annusest avastati väljaheidetes.
English: Contains lactose (see package leaflet for further information) and gelatin.
Estonian: Sisaldab laktoosi (lisainformatsioon vt pakendi infoleht) ja želatiini.
English: In addition, patients treated with Onbrez Breezhaler required significantly less rescue medication, had more days when no rescue medication was needed compared to placebo and had a significantly improved percentage of days with no daytime symptoms.
Estonian: Lisaks vajasid Onbrez Breezhaler'iga ravitud patsiendid oluliselt vähem hooravimit, neil oli platseeboga võrreldes rohkem hooravimi vajaduseta päevi ja neil oli oluliselt suurenenud päevade osakaal, mil puudusid päeva ajal esinevad sümptomid.
English: If you use more Onbrez Breezhaler than you should If you have inhaled too much Onbrez Breezhaler or if someone else uses your capsules, tell your doctor immediately or go to the nearest emergency unit.
Estonian: Kui te kasutate Onbrez Breezhaler'it rohkem kui ette nähtud Kui te olete sisse hinganud liiga palju Onbrez Breezhaler'it või kui keegi teine kasutab teie kapsleid, teavitage sellest otsekohe oma arsti või pöörduge lähima haigla erakorralise meditsiini osakonda.
English: If signs suggesting allergic reactions (in particular, difficulties in breathing or swallowing, swelling of tongue, lips and face, urticaria, skin rash) occur, Onbrez Breezhaler should be discontinued immediately and alternative therapy instituted.
Estonian: Kui ilmnevad allergilisele reaktsioonile viitavad sümptomid (täpsemalt hingamis- või neelamisraskused, keele, huulte ja näo turse, urtikaaria, nahalööve), tuleks Onbrez Breezhaler'i kasutamine koheselt lõpetada ja alustada alternatiivset ravi.
English: Within each system organ class, adverse reactions are ranked by frequency in descending order according to the following convention: Very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000), not known (cannot be estimated from the available data).
Estonian: Igas organsüsteemi klassis on kõrvaltoimed loetletud esinemissageduse vähenemise järjekorras järgmiselt: Väga sage (≥1/10); sage (≥1/100 kuni <1/10); aeg-ajalt (≥1/1000 kuni <1/100); harv (≥1/10 000 kuni <1/1000); väga harv (<1/10 000), teadmata (ei saa hinnata olemasolevate andmete alusel).
English: Study design with a: indacaterol 150 microgram, salmeterol and placebo;
Estonian: Uuringu ülesehitus a: indakaterool 150 mikrogrammi, salmeterool ja platseebo;
English: The mean of the maximum changes in blood glucose were similar between Onbrez Breezhaler and placebo.
Estonian: Vere glükoosisisalduse maksimaalsete muutuste keskmine oli sarnane Onbrez Breezhaler'i ja platseebo puhul.
English: Onbrez Breezhaler has no or negligible influence on the ability to drive and use machines.
Estonian: Onbrez Breezhaler ei mõjuta või mõjutab ebaoluliselt autojuhtimise ja masinate käsitsemise võimet.
English: Concomitant administration of other sympathomimetic medicinal products (alone or as part of combination therapy) may potentiate adverse reactions to Onbrez Breezhaler.
Estonian: Sümpatomimeetilise toimega teiste ravimpreparaatide samaaegsel manustamisel (üksinda või osana kombinatsioonravist) võivad tugevneda Onbrez Breezhaler'i kõrvaltoimed.
English: As with other inhalation therapy, administration of Onbrez Breezhaler may result in paradoxical bronchospasm that may be life-threatening.
Estonian: Nagu igasuguse inhaleeritava ravi puhul, võib Onbrez Breezhaler'i manustamisel tekkida paradoksaalne bronhospasm, mis võib olla eluohtlik.
English: Systemic exposures (AUC) in rats and mice at the no-observed adverse effect levels in these studies were at least 7- and 49-fold higher, respectively, than in humans treated with Onbrez Breezhaler once a day at a dose of 300 microgram.
Estonian: Süsteemse ekspositsiooni (AUC) väärtused rottidel ja hiirtel, mis ei põhjustanud kõrvaltoimete teket nendes uuringutes, olid vastavalt vähemalt 7 ja 49 korda suuremad kui inimestel, kes said ravi Onbrez Breezhaler'iga üks kord päevas annuses 300 mikrogrammi.
English: In vitro studies have shown that indacaterol, a long-acting beta2-adrenergic agonist, has more than 24-fold greater agonist activity at beta2-receptors compared to beta1-receptors and 20-fold greater agonist activity compared to beta3receptors.
Estonian: In vitro uuringud on näidanud, et pikatoimelisel beeta-2-adrenomimeetikumil indakateroolil on enam kui 24 korda suurem agonistlik toime beeta2-retseptorite kui beeta1-retseptorite suhtes ning 20 korda suurem agonistlik toime kui beeta3-retseptorite suhtes.
English: In this pack, you will find an inhaler and capsules (in blisters) that contain the medicine as inhalation powder.
Estonian: Sellest pakendist leiate inhalaatori ja kapslid (blistrites), mis sisaldavad ravimit inhaleeritava pulbrina.
English: Onbrez Breezhaler capsules must always be stored in the blister, and only removed immediately before use.
Estonian: Onbrez Breezhaler kapsleid tuleb alati hoida blistris ja eemaldada need blistrist alles vahetult enne kasutamist.
English: c: indacaterol 300 microgram, formoterol and placebo MCID = minimal clinically important difference (≥1 point change in TDI, ≥4 point change in SGRQ) n/e= not evaluated at six months
Estonian: MCID = minimaalne kliiniliselt oluline erinevus (≥1 punkti muutus - TDI, ≥4 punkti muutusSGRQ) n/e= ei hinnatud kuuendal kuul
English: Onbrez Breezhaler is a long-acting beta2-adrenergic agonist, which is only indicated for COPD and should not be used in asthma due to the absence of long-term outcome data in asthma.
Estonian: Onbrez Breezhaler on pikatoimeline beeta-2-adrenomimeetikum, mis on näidustatud ainult KOKi raviks ja seda ei tohi kasutada astma raviks, sest puuduvad andmed pikaajalise kasutamise kohta astma korral.
English: Onbrez Breezhaler, administered once a day at doses of 150 and 300 microgram consistently provided clinically significant improvements in lung function (as measured by the forced expiratory volume in one second, FEV1) over 24 hours across a number of clinical pharmacodynamic and efficacy studies.
Estonian: Onbrez Breezhaler, mida manustati üks kord päevas annustes 150 ja 300 mikrogrammi, viis järjekindlalt kopsufunktsiooni kliiniliselt olulise paranemiseni (mida mõõdeti forsseeritud ekspiratoorse mahu järgi ühes sekundis, FEV1) 24 tunni jooksul mitmetes kliinilistes farmakodünaamika ja efektiivsuse uuringutes.
English: The magnitude of exposure increases due to interactions does not raise any safety concerns given the safety experience of treatment with Onbrez Breezhaler in clinical studies of up to one year at doses up to twice the maximum recommended therapeutic dose.
Estonian: Koostoimetest tingitud ekspositsiooni suurenemise ulatus ei tõstata ohutusalaseid küsimusi, kuna Onbrez Breezhaler'i kasutamine kliinilistes uuringutes kuni ühe aasta vältel maksimaalsest soovitatavast terapeutilisest annusest kuni kaks korda suuremates annustes oli ohutu.
English: Driving and using machines It is unlikely that Onbrez Breezhaler will affect your ability to drive and use machines.
Estonian: Autojuhtimine ja masinatega töötamine On ebatõenäoline, et Onbrez Breezhaler võiks mõjutada autojuhtimise ja masinatega töötamise võimet.
English: What Onbrez Breezhaler looks like and content of the pack In this pack, you will find an inhaler, together with capsules in blisters.
Estonian: Kuidas Onbrez Breezhaler välja näeb ja pakendi sisu Sellest pakendist leiate inhalaatori ja kapslid blistrites.
English: As demonstrated in 605 patients with COPD in a 26-week, double-blind, placebo-controlled Phase III study, there was no clinically relevant difference in the development of arrhythmic events monitored over 24 hours, at baseline and up to 3 times during the 26-week treatment period, between patients receiving recommended doses of Onbrez Breezhaler treatment and those patients who received placebo or treatment with tiotropium.
Estonian: Nagu demonstreeriti 605 KOKihaige osalusega 26-nädalases, topeltpimedas, platseeboga kontrollitud III faasi uuringus, puudus kliiniliselt oluline erinevus arütmiate tekke osas 24 tunni jooksul, uuringu alguses ja kuni kolmel korral 26-nädalase raviperioodi jooksul Onbrez Breezhaler'i soovitatud annustega ravi saanud ja platseebot või tiotroopiumravi saanud patsientide vahel.
English: Treatment comparison compared to placebo showed a ratio of rates of 0.68 (95% CI [ 0.47, 0.98]; p-value 0.036) and 0.74 (95% CI [0.56, 0.96]; pvalue 0.026) for 150 microgram and 300 microgram, respectively.
Estonian: Ravimi võrdlus platseeboga näitas 0,68 (95% CI [0,47, 0,98]; pväärtus 0,036) ja 0,74 (95% CI [0,56, 0,96]; p-väärtus 0,026) vastavalt 150 mikrogrammi ja 300 mikrogrammi puhul.
English: The inhalation of the content of one 300 microgram capsule once a day, using the Onbrez Breezhaler inhaler has been shown to provide additional clinical benefit with regard to breathlessness, particularly for patients with severe COPD.
Estonian: Ühe 300-mikrogrammise kapsli sisu inhaleerimisel üks kord päevas Onbrez Breezhaler inhalaatorist on saadud täiendavat kliinilist kasu hingelduse leevendamisel, eriti raske KOKiga patsientidel.
English: Although indacaterol did not affect general reproductive performance in a rat fertility study, a decrease in the number of pregnant F1 offspring was observed in the peri- and post-developmental rat study at an exposure 14-fold higher than in humans treated with Onbrez Breezhaler.
Estonian: Kuigi indakaterool ei mõjutanud üldist reproduktsioonivõimet rottidel läbi viidud fertiilsusuuringutes, täheldati Onbrez Breezhaler'iga ravitud rottidel sünnieelse ja-järgse arengu uuringus F1 põlvkonna rottidel tiinete järeltulijate arvu langust 14 korda kõrgema ekspositsiooniga kui inimestel.
English: If paradoxical bronchospasm occurs Onbrez Breezhaler should be discontinued immediately and alternative therapy substituted.
Estonian: Paradoksaalse bronhospasmi tekkimisel tuleb Onbrez Breezhaler'i kasutamine otsekohe lõpetada ja alustada alternatiivset ravi.
English: The European Medicines Agency has waived the obligation to submit the results of studies with Onbrez Breezhaler in all subsets of the paediatric population in chronic obstructive pulmonary disease (COPD) (see section 4.2 for information on paediatric use).
Estonian: Euroopa Ravimiamet ei kohusta esitama Onbrez Breezhaler'iga läbi viidud uuringute tulemusei laste kõikide alarühmade kohta kroonilise obstruktiivse kopsuhaiguse (KOK) korral (teave lastel kasutamise kohta: vt lõik 4.2).
English: Do not wash your inhaler with water.
Estonian: Ärge peske inhalaatorit veega.
English: After you have inhaled the medicine:
Estonian: Kui olete ravimi sisse hinganud:
English: Onbrez Breezhaler should not be used in conjunction with other long-acting beta2-adrenergic agonists or medicinal products containing long-acting beta2-adrenergic agonists.
Estonian: Onbrez Breezhaler'it ei tohi kasutada koos teiste pikatoimeliste beeta-2-adrenomimeetikumidega või ravimitega, mis sisaldavad pikatoimelisi beeta-2-adrenomimeetikume.
English: Although no clinically relevant effect on the cardiovascular system is usually seen after the administration of Onbrez Breezhaler at the recommended doses, as with other beta2-adrenergic agonists, indacaterol should be used with caution in patients with cardiovascular disorders (coronary artery disease, acute myocardial infarction, cardiac arrhythmias, hypertension), in patients with convulsive disorders or thyrotoxicosis, and in patients who are unusually responsive to beta2adrenergic agonists.
Estonian: Kuigi Onbrez Breezhaler'i soovitatavate annuste manustamise järgselt ei täheldata tavaliselt kliiniliselt olulist toimet kardiovaskulaarsüsteemile, tuleb indakaterooli sarnaselt teiste beeta-2-adrenomimeetikumidega kasutada ettevaatlikult patsientidel, kellel esinevad kardiovaskulaarsed haigused (koronaartõbi, äge müokardiinfarkt, südame rütmihäired, hüpertensioon), krambiseisundid või türeotoksikoos, ning samuti patsientidel, kes on ebatavaliselt tundlikud beeta-2-adrenomimeetikumide suhtes.
English: Onbrez Breezhaler was shown to reduce lung hyperinflation, resulting in increased inspiratory capacity during exercise and at rest, compared to placebo.
Estonian: Onbrez Breezhaler vähendas kopsude hüperinflatsiooni, mille tulemusena suurenes inspiratoorne kapatsiteet vastavalt koormusel ja puhkeolekus võrreldes platseeboga.
English: The 24-hour bronchodilator effect of Onbrez Breezhaler was maintained from the first dose throughout a one-year treatment period with no evidence of loss in efficacy (tachyphylaxis).
Estonian: Onbrez Breezhaler'i 24-tunnine bronhe lõõgastav toime püsis esimesest annusest kuni üheaastase raviperioodi lõpuni, ilma et oleks ilmnenud toime kadumist (tahhüfülaksia).
English: Onbrez Breezhaler has not been investigated in patients with not well controlled diabetes mellitus.
Estonian: Onbrez Breezhaler'i kasutamist ei ole uuritud halvasti kontrollitud diabeediga patsientidel.
English: At 600 microgram once-daily, the safety profile of Onbrez Breezhaler was overall similar to that of recommended doses.
Estonian: 600 mikrogrammi üks kord päevas annuse korral oli Onbrez Breezhaler'i ohutusprofiil üldiselt sarnane soovitatud annuste puhul täheldatuga.
English: Upon initiation of treatment with Onbrez Breezhaler plasma glucose should be monitored more closely in diabetic patients.
Estonian: Onbrez Breezhaler'iga ravi alustamise järgselt tuleb diabeetikutel hoolikamalt jälgida plasma glükoosisisaldust.
English: What Onbrez Breezhaler is and what it is used for What you need to know before you use Onbrez Breezhaler How to use Onbrez Breezhaler Possible side effects
Estonian: Mis ravim on Onbrez Breezhaler ja milleks seda kasutatakse Mida on vaja teada enne Onbrez Breezhaler'i kasutamist Kuidas Onbrez Breezhaler'it kasutada Võimalikud kõrvaltoimed
English: Formoterol twice a day
Estonian: Formoteroo l 12 2x päevas
English: Therefore, long-acting beta2-adrenergic agonists such as Onbrez Breezhaler should be used with caution in patients with known or suspected prolongation of the QT interval or treated with medicinal products affecting the QT interval.
Estonian: Seega tuleb pikatoimelisi beeta-2-adrenomimeetikume kasutada ettevaatusega patsientidel, kellel esineb või kahtlustatakse QT-intervalli pikenemist või kes kasutavad QT-intervalli mõjutavaid ravimpreparaate.
English: In the event of deterioration of COPD during treatment with Onbrez Breezhaler, a reevaluation of the patient and of the COPD treatment regimen should be undertaken.
Estonian: Kui ravi ajal Onbrez Breezhaler'iga tekib KOKi süvenemine, tuleb patsiendi seisundit ja KOKi raviskeemi uuesti hinnata.
English: A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from Onbrez Breezhaler therapy, taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.
Estonian: Rinnaga toitmise katkestamine või ravi katkestamine/jätkamine, tuleb otsustada arvestades imetamise kasu lapsele ja ravi kasu naisele.
English: Your Onbrez Breezhaler pack: Each Onbrez Breezhaler pack contains: one Onbrez Breezhaler inhaler one or more blisters containing Onbrez Breezhaler capsules to be used in the inhaler.
Estonian: Onbrez Breezhaler'i pakend: Igas Onbrez Breezhaler'i pakendis sisaldub: üks Onbrez Breezhaler inhalaator, üks või mitu inhalaatoris kasutatavaid Onbrez Breezhaler kapsleid sisaldavat blistrit.
English: Renal impairment No dose adjustment is required for patients with renal impairment.
Estonian: Neerukahjustus Neerukahjustusega patsientidel ei ole vaja annust muuta.
English: The capsules must be administered only using the Onbrez Breezhaler inhaler (see section 6.6).
Estonian: Kapslite manustamiseks tohib kasutada ainult Onbrez Breezhaler inhalaatorit (vt lõik 6.6).
English: How to store Onbrez Breezhaler Contents of the pack and other information
Estonian: Kuidas Onbrez Breezhaler'it säilitada Pakendi sisu ja muu taeve
English: Do not take the inhaler apart.
Estonian: Ärge võtke inhalaatorit osadeks lahti.
English: At the recommended doses, the adverse reaction profile of Onbrez Breezhaler in patients with COPD shows clinically insignificant systemic effects of beta2-adrenergic stimulation.
Estonian: Soovitatud annuste puhul näitab Onbrez Breezhaler'i kõrvaltoimete profiil KOKihaigetel kliiniliselt ebaolulisi süsteemseid toimeid seoses beeta-2-adrenergilise stimulatsiooniga.
English: The recommended dose is the inhalation of the content of one 150 microgram capsule once a day, using the Onbrez Breezhaler inhaler.
Estonian: Soovitatavaks annuseks on ühe 150-mikrogrammise kapsli sisu inhalatsioon üks kord päevas Onbrez Breezhaler inhalaatorist.
English: Other medicines and Onbrez Breezhaler
Estonian: Muud ravimid ja Onbrez Breezhaler
English: The Onbrez Breezhaler Phase III clinical development programme involved patients with a clinical diagnosis of moderate to severe COPD.
Estonian: Onbrez Breezhaler'i III faasi kliinilises arendusprogrammis osalesid patsiendid, kelle kliiniliseks diagnoosiks oli keskmise raskusega või raske KOK.
English: How long to continue your treatment with Onbrez Breezhaler Keep using your treatment with Onbrez Breezhaler for as long as your doctor tells you.
Estonian: Kui kaua tuleb jätkata ravi Onbrez Breezhaler'iga Jätkake ravi Onbrez Breezhaler'iga senikaua, kui arst soovitab.
English: Immediate hypersensitivity reactions have been reported after administration of Onbrez Breezhaler.
Estonian: On teatatud kohestest ülitundlikkusreaktsioonidest pärast Onbrez Breezhaler'i manustamist.
English: The Onbrez Breezhaler inhaler provided with each new prescription should be used.
Estonian: Kasutada tuleb iga uue retseptiga ette nähtud Onbrez Breezhaler inhalaatorit.
English: Paediatric population There is no relevant use of Onbrez Breezhaler in the paediatric population (under 18 years).
Estonian: Puudub Onbrez Breezhaler'i asjakohane kasutus lastel (vanuses alla 18 aasta).
English: Onbrez Breezhaler contains the active substance indacaterol which belongs to a group of medicines called bronchodilators.
Estonian: Onbrez Breezhaler sisaldab toimeainena indakaterooli, mis kuulub bronhodilataatoriteks ehk bronhilõõgastiteks nimetatud ravimite rühma.
English: An increase in the daily dose of Onbrez Breezhaler beyond the maximum dose of 300 microgram is not appropriate.
Estonian: Onbrez Breezhaler'i ööpäevast annust ei tohi suurendada üle maksimaalse annuse, milleks on 300 mikrogrammi.
English: Clinically relevant effects on prolongation of the QTc-interval have not been observed in clinical studies of Onbrez Breezhaler at recommended therapeutic doses (see section 5.1).
Estonian: Onbrez Breezhaler'i kliinilistes uuringutes ei ole soovitatavate terapeutiliste annuste kasutamisel täheldatud kliiniliselt olulisi toimeid QTc-intervalli pikenemisele (vt lõik 5.1).
English: What Onbrez Breezhaler contains - Each Onbrez Breezhaler 150 microgram capsule contains 150 microgram indacaterol as indacaterol maleate.
Estonian: Mida Onbrez Breezhaler sisaldab - Iga Onbrez Breezhaler 150-mikrogrammine kapsel sisaldab 150 mikrogrammi indakaterooli indakateroolmaleaadina.
English: Breezhaler capsules with any other inhaler, and do not use Onbrez Breezhaler inhaler to take any other capsule medicine.
Estonian: Onbrez Breezhaler kapsleid üheski teises inhalaatoris, samuti ärge kasutage Onbrez Breezhaler inhalaatorit ühegi teise kapslites ravimi manustamiseks.
English: Onbrez Breezhaler is not indicated for the treatment of acute episodes of bronchospasm, i.e. as rescue therapy.
Estonian: Onbrez Breezhaler ei ole näidustatud ägedate bronhospasmi episoodide raviks, st hooravimina.
English: There are no data available for use of Onbrez Breezhaler in patients with severe hepatic impairment.
Estonian: Puuduvad andmed Onbrez Breezhaler'i kasutamise kohta raske maksakahjustusega patsientidel.
English: During clinical studies, clinically notable changes in blood glucose were generally more frequent by 1-2% on Onbrez Breezhaler at the recommended doses than on placebo.
Estonian: Kliinilistes uuringutes esines Onbrez Breezhaler'i soovitatavate annuste kasutamisel veresuhkru taseme kliiniliselt väljendunud muutusi üldiselt sagedamini (1...2% võrra) kui platseebo puhul.
English: Onbrez Breezhaler 150 microgram capsules have a black product code “IDL 150” printed above a black bar and a black company logo ( ) printed below the black bar.
Estonian: Onbrez Breezhaler 150-mikrogrammistele kapslitele on trükitud mustas kirjas toote kood „IDL 150“ musta joone kohale ja firma logo ( ) musta joone alla.
English: Onbrez Breezhaler 300 microgram capsules have a blue product code “IDL 300” printed above a blue bar and a blue company logo ( ) printed below the blue bar.
Estonian: Onbrez Breezhaler 300-mikrogrammistele kapslitele on trükitud sinises kirjas toote kood „IDL 300“ sinise joone kohale ja firma logo ( ) sinise joone alla.
English: Always keep the Onbrez Breezhaler inhaler and capsules in a dry place.
Estonian: Hoidke Onbrez Breezhaler inhalaatorit ja kapsleid alati kuivas kohas.
English: Onbrez Breezhaler, administered once a day at doses of 150 microgram and 300 microgram, showed clinically meaningful improvements in lung function.
Estonian: Onbrez Breezhaler'i manustamine üks kord päevas annustes 150 ja 300 mikrogrammi viis kopsufunktsiooni kliiniliselt olulise paranemiseni.
English: Onbrez Breezhaler capsules must not be swallowed.
Estonian: Onbrez Breezhaler kapsleid ei tohi alla neelata.
English: Only use the capsules with the inhaler provided in this pack (Onbrez Breezhaler inhaler).
Estonian: Kasutage kapsleid ainult koos selles pakendis oleva inhalaatoriga (Onbrez Breezhaler inhalaator).
English: • Only use the Onbrez Breezhaler inhaler contained in this pack.
Estonian: • Kasutage ainult selles pakendis sisalduvat Onbrez Breezhaler inhalaatorit.
English: What you need to know before you use Onbrez Breezhaler
Estonian: Mida on vaja teada enne Onbrez Breezhaler'i kasutamist
English: Tiotropium once a day
Estonian: Tiotroopiu m 18 1x päevas
English: Stop using the medicine and tell your doctor immediately if you get tightness of the chest, coughing, wheezing or breathlessness immediately after using the medicine.
Estonian: Kui teil tekib vahetult pärast ravimi kasutamist rindkere pingsus, köha, vilisev hingamine või hingeldus, lõpetage otsekohe ravimi kasutamine ja teavitage sellest oma arsti.
English: - Each Onbrez Breezhaler 300 microgram capsule contains 300 microgram indacaterol as indacaterol maleate.
Estonian: - Iga Onbrez Breezhaler 300-mikrogrammine kapsel sisaldab 300 mikrogrammi indakaterooli indakateroolmaleaadina.
English: medicines called beta blockers that are used for high blood pressure or other heart problems (such as propranolol), or for the eye problem called glaucoma (such as timolol).
Estonian: Teil võivad suurema tõenäosusega tekkida kõrvaltoimed; beeta-blokaatoriteks nimetatud ravimid, mida kasutatakse kõrgvererõhu või teiste südameprobleemide korral (nt propranolool) või glaukoomiks nimetatud silmahaiguse korral (nt timolool); vere kaaliumisisaldust alandavad ravimid.
English: Onbrez Breezhaler contains lactose
Estonian: Onbrez Breezhaler sisaldab laktoosi
English: 10 capsules + 1 inhaler 30 capsules + 1 inhaler
Estonian: 10 kapslit + 1 inhalaator 30 kapslit + 1 inhalaator
English: Show the pack of Onbrez Breezhaler.
Estonian: Näidake Onbrez Breezhaler'i pakendit.